In addition to breast cancer (3), CD44 was considered to be a CSL-cell marker in ovarian (53), prostate (54) and pancreatic cancer (10), and head and neck squamous cell carcinoma (55). Here, CD44 is linked to head and neck squamous cell carcinoma.